Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Registro de resultados prospectivos de fibrose pulmonar idiopática e doença pulmonar intersticial (IPF/ILD-PRO)

9 de novembro de 2026 atualizado por: Duke University

Registro de resultados prospectivos de fibrose pulmonar idiopática (IPF-PRO) e doença pulmonar intersticial fibrosante crônica com fenótipo progressivo (IPF-PRO/ILD-PRO)

The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the third phase of the registry begins, the IPF-PRO registry will enroll additional patients with idiopathic pulmonary fibrosis. This IPF-PRO registry is a prospective registry that will collect information regarding the natural history, health care interactions, participant reported questionnaire data to assess quality of life, and the methods of treatment of participants with a diagnosis of idiopathic pulmonary fibrosis (IPF) or of another chronic fibrosing interstitial lung disease (ILD) with progressive phenotype established at the enrolling centers. In addition, blood samples and chest image studies will be collected and banked for future research projects.

Visão geral do estudo

Status

Recrutamento

Condições

Descrição detalhada

This registry originally enrolled a total of 1002 participants newly diagnosed with IPF and continues to enroll patients with other chronic fibrosing ILDs with newly identified progressive phenotype to reach an enrollment of 1000 patients. Participants will be enrolled in three phases, (IPF-PRO and ILD-PRO) over a span of 8 years at approximately 50 sites experienced in the diagnosis and treatment of ILD in the United States. Enrollment for the original IPF cohort started in 2014 and ended in October 2018, with 1002 total participants enrolled. In the third phase of the registry new enrollment for patients with IPF will restart in 2023-2024 with the plan to enroll up to 1000 new IPF patients, for a total IPF enrollment of 2000. Enrollment for other chronic fibrosing ILDs with newly identified progressive phenotype cohort was initiated in February 2019 and will end when enrollment reaches 1000 participants with the potential of enrolling another 1000 participants with other chronic fibrosing ILDs with newly identified without a progressive phenotype. Data and samples will be collected from participants for approximately 5 years for the IPF cohort. For the chronic fibrosing ILD with progressive phenotype cohort, data and samples will be collected for a minimum of 3 years, up to approximately 5 years. Participant management and treatment decisions will be determined by participants and their health care professionals.

Tipo de estudo

Observacional

Inscrição (Estimado)

3000

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35294
        • Recrutamento
        • University of Alabama - Birmingham
        • Investigador principal:
          • Tejaswini Kulkarni, MD
        • Contato:
    • Arizona
      • Tucson, Arizona, Estados Unidos, 85721
        • Recrutamento
        • University of Arizona
        • Investigador principal:
          • Sally A Suliman, MD
        • Contato:
    • California
      • Los Angeles, California, Estados Unidos, 90033
        • Recrutamento
        • University of Southern California
        • Contato:
        • Investigador principal:
          • Toby Maher, MD
      • Los Angeles, California, Estados Unidos, 90024
        • Recrutamento
        • University of California - Los Angeles
        • Investigador principal:
          • John Belperio, MD
        • Contato:
      • Stanford, California, Estados Unidos, 94305
        • Recrutamento
        • Stanford University
        • Investigador principal:
          • Rishi Raj, MD
        • Contato:
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80045
        • Recrutamento
        • University of Colorado
        • Investigador principal:
          • Joyce Lee, MD
        • Contato:
    • Connecticut
      • New Haven, Connecticut, Estados Unidos, 06520
        • Recrutamento
        • Yale University
        • Investigador principal:
          • Mridu Gulati, MD
        • Contato:
    • Florida
      • Gainesville, Florida, Estados Unidos, 32610-3175
      • Tampa, Florida, Estados Unidos, 33606
        • Recrutamento
        • University of South Florida
        • Investigador principal:
          • Jose D Herazo-Maya, MD
        • Contato:
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
        • Recrutamento
        • Emory University
        • Contato:
        • Investigador principal:
          • Srihari Veeraraghavan, MD
      • Austell, Georgia, Estados Unidos, 30106
        • Recrutamento
        • Piedmont Healthcare
        • Investigador principal:
          • Amy Case, MD
        • Contato:
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60637
        • Recrutamento
        • University of Chicago
        • Investigador principal:
          • Mary Strek, MD
        • Contato:
      • Evanston, Illinois, Estados Unidos, 60611
        • Recrutamento
        • Northwestern University
        • Contato:
        • Investigador principal:
          • Bradford Bemiss, MD
      • Maywood, Illinois, Estados Unidos, 60153
        • Recrutamento
        • Loyola University Health System
        • Investigador principal:
          • Daniel Dilling, MD
        • Contato:
    • Kansas
      • Kansas City, Kansas, Estados Unidos, 66160
        • Rescindido
        • University of Kansas
    • Kentucky
      • Lexington, Kentucky, Estados Unidos, 40536
        • Recrutamento
        • University of Kentucky
        • Investigador principal:
          • Girish Nair, MD
        • Contato:
    • Louisiana
      • New Orleans, Louisiana, Estados Unidos, 70112
        • Recrutamento
        • Tulane University
        • Investigador principal:
          • Joe Lasky, MD
        • Contato:
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • Ativo, não recrutando
        • University of Michigan
      • Detroit, Michigan, Estados Unidos, 48202
        • Recrutamento
        • Henry Ford Health
        • Contato:
        • Investigador principal:
          • Asif Abdul Hameed, MD
    • Minnesota
      • Minneapolis, Minnesota, Estados Unidos, 55455
        • Recrutamento
        • University of Minnesota
        • Contato:
        • Investigador principal:
          • Hyum Kim, MD
    • Mississippi
      • Jackson, Mississippi, Estados Unidos, 39216
        • Recrutamento
        • University of Mississippi Medical Center
        • Investigador principal:
          • Kimberly Dobbs, MD
        • Contato:
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63110
        • Recrutamento
        • Washington University
        • Investigador principal:
          • Tonya Russell, MD
        • Contato:
    • New York
      • New York, New York, Estados Unidos, 10065
        • Recrutamento
        • Weill Medical College of Cornell University
        • Investigador principal:
          • Kerri Aronson, MD
        • Contato:
      • New York, New York, Estados Unidos, 10016
        • Ativo, não recrutando
        • NYU Medical Center
    • North Carolina
      • Chapel Hill, North Carolina, Estados Unidos, 27514
      • Durham, North Carolina, Estados Unidos, 27705
        • Recrutamento
        • Duke University
        • Investigador principal:
          • Lake Morrison, MD
        • Contato:
      • Greensboro, North Carolina, Estados Unidos, 27403
        • Recrutamento
        • Pulmonix LLC
        • Investigador principal:
          • Murali Ramaswamy, MD
        • Contato:
      • Wilmington, North Carolina, Estados Unidos, 28401
        • Rescindido
        • PMG Research
      • Winston-Salem, North Carolina, Estados Unidos, 27157
        • Recrutamento
        • Wake Forest Baptist Health
        • Contato:
        • Investigador principal:
          • Andrew Namen, MD
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45267
        • Ativo, não recrutando
        • University of Cincinnati Medical Center
      • Cleveland, Ohio, Estados Unidos, 44195
        • Recrutamento
        • Cleveland Clinic
        • Investigador principal:
          • Brian Southern, MD
        • Contato:
      • Columbus, Ohio, Estados Unidos, 43210
        • Recrutamento
        • The Ohio State University
        • Contato:
        • Investigador principal:
          • John Odackal
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73104
        • Recrutamento
        • University of Oklahoma
        • Investigador principal:
          • Jad Kebbe, MD
        • Contato:
    • Oregon
      • Portland, Oregon, Estados Unidos, 97220
        • Recrutamento
        • Oregon Clinic
        • Investigador principal:
          • David Hotchkin, MD
        • Contato:
    • Pennsylvania
      • Hershey, Pennsylvania, Estados Unidos, 17033
        • Recrutamento
        • Penn State College of Medicine - Hershey
        • Investigador principal:
          • Rebecca Bascom, MD
        • Contato:
      • Philadelphia, Pennsylvania, Estados Unidos, 19140
        • Recrutamento
        • Temple University
        • Investigador principal:
          • Rachel Criner, MD
        • Contato:
      • Philadelphia, Pennsylvania, Estados Unidos, 19144
    • South Carolina
      • Charleston, South Carolina, Estados Unidos, 29425
        • Recrutamento
        • Medical University of South Carolina
        • Investigador principal:
          • Timothy Whelan, MD
        • Contato:
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37232
        • Recrutamento
        • Vanderbilt University
        • Contato:
        • Investigador principal:
          • Justin Hewlett, MD
    • Texas
      • Dallas, Texas, Estados Unidos, 75235
        • Recrutamento
        • University of Texas Southwestern
        • Investigador principal:
          • John Fitzgerald, MD
        • Contato:
      • Dallas, Texas, Estados Unidos, 75246
        • Recrutamento
        • Baylor University Medical Center at Dallas
        • Investigador principal:
          • Yolanda Mageto, MD
        • Contato:
      • Houston, Texas, Estados Unidos, 77030
        • Recrutamento
        • Baylor College of Medicine
        • Investigador principal:
          • Ivan Rosas, MD
        • Contato:
      • Houston, Texas, Estados Unidos, 77030
        • Recrutamento
        • Houston Methodist Lung Center
        • Investigador principal:
          • Zeenat Safdar, MD
        • Contato:
      • Houston, Texas, Estados Unidos, 77030
        • Recrutamento
        • The University of Texas Health Science Center At Houston
        • Investigador principal:
          • Rodeo Abrencillo, MD
        • Contato:
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84108
        • Recrutamento
        • University of Utah
        • Contato:
        • Investigador principal:
          • Mary Beth Langer, MD
      • Salt Lake City, Utah, Estados Unidos, 84111
        • Recrutamento
        • Intermountain Health
        • Contato:
        • Investigador principal:
          • Erin Blackstock, MD
    • Vermont
      • Colchester, Vermont, Estados Unidos, 05446
        • Ativo, não recrutando
        • University of Vermont Lung Center
    • Virginia
      • Charlottesville, Virginia, Estados Unidos, 22908
        • Ativo, não recrutando
        • University from Virginia
      • Falls Church, Virginia, Estados Unidos, 22042-3307
        • Recrutamento
        • Inova Health Care Services
        • Contato:
        • Investigador principal:
          • Jared Wilkinson, MD
    • Wisconsin
      • Milwaukee, Wisconsin, Estados Unidos, 53226
        • Ativo, não recrutando
        • The Medical College of Wisconsin

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

21 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

Subjects with a new diagnosis of IPF or a non- IPF chronic fibrosing ILD established at the time of enrollment in the registry are eligible for participation in the IPF-PRO/ILD-PRO registry if the participant meets the selection criteria.

Descrição

Inclusion Criteria:

  • Willing and able to provide informed consent

  • Established a new diagnosis (within 12 months) of IPF by the enrolling center.

  • Age 21 years or older, or

  • Diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype during the last 24 months by the enrolling center that meets the following criteria:

    • Chronic fibrosing ILD as defined by reticular abnormality with traction bronchiectasis with or without honeycombing confirmed by chest HRCT scan and/or lung biopsy.

    • Progressive phenotype as defined by fulfilling at least one of the criteria below of fibrotic changes (progression set point) within the last 24 months regardless of treatment considered appropriate in individual ILDs (8):

      • decline in FVC % predicted (% pred) based on ≥10% relative decline
      • decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with worsening of respiratory symptoms as assessed by the site investigator
      • decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator
      • decline in DLCO % pred based on≥ 10% relative decline
      • worsening of respiratory symptoms as well as increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator independent of FVC change.

The relative decline for FVC % predicted is calculated using the formula:

Relative Decline= (FVC % Pred (Reference)-FVC % Pred (Screening))/(FVC % Pred (Reference))×100%, where FVC % Pred (Reference) is the greatest measurement of FVC % predicted in the 24 months prior to screening and FVC % Pred (Screening) is the measurement of FVC % predicted at screening.

The relative decline for DLCO % predicted is calculated using the formula:

Relative Decline= (DLCO % Pred (Reference)-DLCO % Pred (Screening))/(DLCO % Pred (Reference))×100%, Where DLCO % Pred (Reference) is the greatest measurement of DLCO % Pred in the 24 months prior to screening and DLCO % Pred (Screening) is the measurement of DLCO % Pred at screening

Exclusion Criteria:

  • Malignancy, treated or untreated, other than skin or early -stage prostate cancer, within the past 5 years
  • Currently listed for lung transplantation at the time of enrollment
  • Currently enrolled in an interventional clinical trial at the time of enrollment in this registry
  • For the additional IPF cohort of 1000 individuals, previous enrollment in this registry.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: COHORT
  • Perspectivas de Tempo: PROSPECTIVE

Coortes e Intervenções

Grupo / Coorte
Subjects with a new IPF diagnosis

Subjects with a new diagnosis of IPF established at the time of enrollment in the registry

Subjects with a non-IPF ILD diagnosis

Subjects with a diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype

New Subjects with a new IPF diagnosis

Subjects with a new diagnosis of IPF established at the time of enrollment in the registry not previously enrolled in the registry.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Data on natural history of IPF & non-IPF chronic fibrosing ILD
Prazo: End of Study (3 years after last patient will be enrolled)

Characterize and describe the natural history of patients with a recent confirmed diagnosis of IPF, with emphasis on demographics, co-morbidities, medications, and risks for disease progression or death.

End of Study (3 years after last patient will be enrolled)
Data on current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD
Prazo: End of Study (3 years after last patient will be enrolled)

Understand the current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD

End of Study (3 years after last patient will be enrolled)
Data on impact of IPF & non- IPF chronic fibrosing ILD on patient quality of life.
Prazo: End of Study (3 years after last patient will be enrolled)

Describe the impact of IPF & non- IPF chronic fibrosing ILD on patient quality-of-life (QOL).

End of Study (3 years after last patient will be enrolled)
Blood samples for future research.
Prazo: End of Study (3 years after last patient will be enrolled)

Collect longitudinal bio-samples for future research on disease presentation, progression, and subject response to clinical interventions.

End of Study (3 years after last patient will be enrolled)
HRCT images for future research (for non-IPF chronic fibrosing ILD, and new IPF patients cohort)
Prazo: End of Study (3 years after last patient will be enrolled)

Collect longitudinal HRCT images for future research

End of Study (3 years after last patient will be enrolled)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Data on management practices compared to existing guidelines.
Prazo: End of Study (3 years after last patient will be enrolled)

Compare disease-specific management practices with existing guidelines.

End of Study (3 years after last patient will be enrolled)
Data on center-specific practices on outcomes.
Prazo: End of Study (3 years after last patient will be enrolled)

Determine the influence of center-specific practices on patient outcomes.

End of Study (3 years after last patient will be enrolled)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Scott Palmer, MD, Duke Clinical Research Institute, Duke University

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de junho de 2014

Conclusão Primária (Estimado)

1 de janeiro de 2028

Conclusão do estudo (Estimado)

1 de janeiro de 2031

Datas de inscrição no estudo

Enviado pela primeira vez

31 de julho de 2013

Enviado pela primeira vez que atendeu aos critérios de CQ

1 de agosto de 2013

Primeira postagem (Estimado)

5 de agosto de 2013

Atualizações de registro de estudo

Última Atualização Postada (Real)

12 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

9 de novembro de 2026

Última verificação

1 de julho de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • Pro00046131
  • 1199.174 (Outro identificador: DCRI)

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .